Abstract Details

Title Postural Orthostatic Tachycardia Syndrome and Vitamin D Deficiency

Topic Autonomic Disorders

Presentation(s) P03 - (-)

Poster/Presentation
Number 034

Objective

Background BACKGROUND: VDD is common, and has been associated with cardiovascular, autoimmune, and osteopenic disease. There are anecdotal reports of an association between VDD and POTS, but formal investigations are lacking. Because the pathophysiology of POTS remains elusive, such an association if confirmed provides an etiologic hypothesis with treatment implications.

Design/Methods DESIGN/METHODS: The electronic medical records of 84 cases of POTS were reviewed, and Vitamin D levels recorded when available. The characteristics of those with and without VDD were compared, and the prevalence of VDD was compared to established population data.

Results RESULTS: Subjects were aged 19 to 56 years, median age 28, including 73 females (87%) and 11 males (13%). Vitamin D levels were available in 60 patients (52 females, 8 males). 14/60 (23%) had VDD, a proportion significantly lower than the reported prevalence of VDD (41-70%). There was no association found between VDD and age, gender, heart rate increment on up-tilt, CASS score, fatigue, or myofascial pain. Males had lower average vitamin D levels than females (p=0.0447), a relationship not seen in population studies. VO2max% was lower among those with VDD, which regressed with VO2max%.

Conclusions CONCLUSIONS: Overall, an association between POTS and VDD is not found. Thefrequency of VDD is lower among POTS patients than among the general population. Several cardinal clinical features of POTS were to be independent from VDD in our sample. While Vitamin D levels are seen to be lower on average among men with POTS than women, this is unlikely of clinical significance since the rate of VDD was not associated with gender. The relationship between Vit D levels and VO2max% suggests that VDD is associated with, but is not necessarily the cause of deconditioning.

Authors/Disclosures
Adam Loavenbruck, MD (University of Minnesota) PRESENTER	Dr. Loavenbruck has nothing to disclose.
Wolfgang Singer, MD, FAAN (Mayo Clinic)	Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. The institution of Dr. Singer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Yoda. Dr. Singer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theravance. Dr. Singer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ferrer. The institution of Dr. Singer has received research support from NIH. The institution of Dr. Singer has received research support from FDA. The institution of Dr. Singer has received research support from Michael J. Fox Foundation. Dr. Singer has received intellectual property interests from a discovery or technology relating to health care.
Phillip A. Low, MD, FAAN (Mayo Clinic)	Dr. Low has nothing to disclose.
Paola Sandroni, MD, PhD, FAAN (Mayo Clinic)	Dr. Sandroni has nothing to disclose.
	No disclosure on file

��ɫ��

��ɫ��